Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells

Cancer Cell International

Mitsuru Miyachi¹  Shigeki Yagyu¹  Tomoko Iehara¹  Hajime Hosoi¹  Kunihiko Tsuchiya¹  Kazutaka Ouchi¹  Yasumichi Kuwahara¹  Ken Kikuchi¹ 

[1] Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine;

关键词: HMGA2;    Fusion-negative rhabdomyosarcoma;    Netropsin;   

DOI  :  10.1186/s12935-020-01282-z

来源: DOAJ

【 摘 要 】

Abstract Background Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. There are two subtypes, fusion gene-positive RMS (FP-RMS) and fusion gene-negative RMS (FN-RMS), depending on the presence of a fusion gene, either PAX3-FOXO1 or PAX7-FOXO1. These fusion genes are thought to be oncogenic drivers of FP-RMS. By contrast, the underlying mechanism of FN-RMS has not been thoroughly investigated. It has recently been shown that HMGA2 is specifically positive in pathological tissue from FN-RMS, but the role of HMGA2 in FN-RMS remains to be clarified. Methods In this study, we used FN-RMS cell lines to investigate the function of HMGA2. Gene expression, cell growth, cell cycle, myogenic differentiation, tumor formation in vivo, and cell viability under drug treatment were assessed. Results We found that HMGA2 was highly expressed in FN-RMS cells compared with FP-RMS cells and that knockdown of HMGA2 in FN-RMS cells inhibited cell growth and induced G1 phase accumulation in the cell cycle and myogenic differentiation. Additionally, we showed using both gain-of-function and loss-of-function assays that HMGA2 was required for tumor formation in vivo. Consistent with these findings, the HMGA2 inhibitor netropsin inhibited the cell growth of FN-RMS. Conclusions Our results suggest that HMGA2 has important role in the oncogenicity of FP-RMS and may be a potential therapeutic target in patients with FN-RMS.

【 授权许可】

Unknown